178 related articles for article (PubMed ID: 23974721)
1. DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells.
Koshio J; Kagamu H; Nozaki K; Saida Y; Tanaka T; Shoji S; Igarashi N; Miura S; Okajima M; Watanabe S; Yoshizawa H; Narita I
Cancer Immunol Immunother; 2013 Oct; 62(10):1619-28. PubMed ID: 23974721
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with CD133(+) melanoma induces specific Th17 and Th1 cell-mediated antitumor reactivity against parental tumor.
Miyabayashi T; Kagamu H; Koshio J; Ichikawa K; Baba J; Watanabe S; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Narita I
Cancer Immunol Immunother; 2011 Nov; 60(11):1597-608. PubMed ID: 21691723
[TBL] [Abstract][Full Text] [Related]
3. DDX4 (DEAD box polypeptide 4) colocalizes with cancer stem cell marker CD133 in ovarian cancers.
Kim KH; Kang YJ; Jo JO; Ock MS; Moon SH; Suh DS; Yoon MS; Park ES; Jeong N; Eo WK; Kim HY; Cha HJ
Biochem Biophys Res Commun; 2014 May; 447(2):315-22. PubMed ID: 24727449
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
5. Annexin A3 as a potential target for immunotherapy of liver cancer stem-like cells.
Pan QZ; Pan K; Wang QJ; Weng DS; Zhao JJ; Zheng HX; Zhang XF; Jiang SS; Lv L; Tang Y; Li YQ; He J; Liu Q; Chen CL; Zhang HX; Xia JC
Stem Cells; 2015 Feb; 33(2):354-66. PubMed ID: 25267273
[TBL] [Abstract][Full Text] [Related]
6. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells.
Pietra G; Manzini C; Vitale M; Balsamo M; Ognio E; Boitano M; Queirolo P; Moretta L; Mingari MC
Int Immunol; 2009 Jul; 21(7):793-801. PubMed ID: 19491215
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
Dashti A; Ebrahimi M; Hadjati J; Memarnejadian A; Moazzeni SM
Cancer Lett; 2016 Apr; 374(1):175-185. PubMed ID: 26803056
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
[TBL] [Abstract][Full Text] [Related]
9. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations.
Nozaki K; Kagamu H; Shoji S; Igarashi N; Ohtsubo A; Okajima M; Miura S; Watanabe S; Yoshizawa H; Narita I
PLoS One; 2014; 9(10):e111019. PubMed ID: 25343452
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells.
Sun JC; Pan K; Chen MS; Wang QJ; Wang H; Ma HQ; Li YQ; Liang XT; Li JJ; Zhao JJ; Chen YB; Pang XH; Liu WL; Cao Y; Guan XY; Lian QZ; Xia JC
Cancer Biol Ther; 2010 Aug; 10(4):368-75. PubMed ID: 20581468
[TBL] [Abstract][Full Text] [Related]
11. Isolation and identification of cancer stem-like cells from murine melanoma cell lines.
Dou J; Pan M; Wen P; Li Y; Tang Q; Chu L; Zhao F; Jiang C; Hu W; Hu K; Gu N
Cell Mol Immunol; 2007 Dec; 4(6):467-72. PubMed ID: 18163959
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel human leukocyte antigen-A*0201-restricted, cytotoxic T lymphocyte epitopes on CD133 for cancer stem cell immunotherapy.
Ji J; Judkowski VA; Liu G; Wang H; Bunying A; Li Z; Xu M; Bender J; Pinilla C; Yu JS
Stem Cells Transl Med; 2014 Mar; 3(3):356-64. PubMed ID: 24375541
[TBL] [Abstract][Full Text] [Related]
13. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-92 Expression in CD133
Shidal C; Singh NP; Nagarkatti P; Nagarkatti M
Cancer Res; 2019 Jul; 79(14):3622-3635. PubMed ID: 31015227
[TBL] [Abstract][Full Text] [Related]
15. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.
Kemper K; Sprick MR; de Bree M; Scopelliti A; Vermeulen L; Hoek M; Zeilstra J; Pals ST; Mehmet H; Stassi G; Medema JP
Cancer Res; 2010 Jan; 70(2):719-29. PubMed ID: 20068153
[TBL] [Abstract][Full Text] [Related]
16. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
[TBL] [Abstract][Full Text] [Related]
17. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Shi C; Tian R; Wang M; Wang X; Jiang J; Zhang Z; Li X; He Z; Gong W; Qin R
Cancer Biol Ther; 2010 Dec; 10(11):1182-90. PubMed ID: 20948317
[TBL] [Abstract][Full Text] [Related]
18. Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine.
Zhao F; Zhang R; Wang J; Wu D; Pan M; Li M; Guo M; Dou J
Int Immunopharmacol; 2017 Nov; 52():238-244. PubMed ID: 28950176
[TBL] [Abstract][Full Text] [Related]
19. The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma.
Hua W; Yao Y; Chu Y; Zhong P; Sheng X; Xiao B; Wu J; Yang B; Mao Y; Zhou L
J Neurooncol; 2011 Nov; 105(2):149-57. PubMed ID: 21479962
[TBL] [Abstract][Full Text] [Related]
20. Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.
Prasad S; Gaedicke S; Machein M; Mittler G; Braun F; Hettich M; Firat E; Klingner K; Schüler J; Wider D; Wäsch RM; Herold-Mende C; Elsässer-Beile U; Niedermann G
Cancer Res; 2015 Jun; 75(11):2166-76. PubMed ID: 25840983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
